Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label prophylaxis study of vonicog alfa in severe von Willebrand disease
NL-OMON47063Phase 3Recruiting
- Sponsor
- Baxalta
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Baxalta. Started Jan 2018; status: recruiting.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NL-OMON47063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47063.